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Abstract
Background. There is little evidence for superior outcome
of one dialysis therapy versus another. Still, nephrologists
havetoprescribedialysiseveryday.Itisthereforeofinterest
to ascertain the opinion among nephrology professionals
regarding which therapy they consider to be the best and to
compare this to reality.
Methods.Wedesignedasurveyaddressingthesequestions
and distributed it at five international dialysis and nephrol-
ogy congresses during 2007.
Results. Responses were collected from 6595 delegates,
57% physicians and 28% nurses. Peritoneal dialysis (PD)
wasconsideredthebestinitialdialysistherapyforaplanned
startinatypicalpatient.Thedialysistreatmentchosentobe
best for long-term use was home/self-care dialysis applied
>3 times/week. The best extracorporeal form of dialysis
among European respondents was high-volume haemodi-
afiltration (HDF), while the Asians and Americans gave
preference to high-flux haemodialysis (HD). Only 7% pre-
ferred low-flux HD. Finally, the respondents were asked
what level of evidence they would require to consider one
form of dialysis superior to another. The majority wanted
hard evidence, i.e. improved survival, to make such a
distinction.
Conclusions. The view of nephrology professionals on the
value of different dialysis therapies reflects current scien-
tific discussions. They consider PD to be the best initial
therapy and frequent application of home/self-care dialysis
to be the best long-term therapy. High-flux membranes are
strongly preferred for any extracorporeal form of therapy,
and HDF seems to be the modality of choice among Euro-
peans. The opinions expressed are far from reality, which
we interpret to show that non-medical factors have a strong
impact on treatment allocation.
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Introduction
Sincethebirthofchronicdialysistreatmentalmost50years
ago, significant technological and medical advancements
have influenced the way patients are dialyzed, but the ba-
sic questions about what and how much to remove from
blood and how and how often to do so are still without an
answer. Although major studies have been done to provide
the missing evidence, the result has so far been inconclu-
sive. Still, nephrologists have to prescribe dialysis for their
patients every day, and while on one hand there is little ev-
idence for superior outcome of one dialysis therapy versus
another,treatmentpersonalizationandspecificprescription
for selected patients seems to be a key towards improving
outcomes.
Inahealthcareenvironmentwithsevereeconomiclimita-
tions, the lack of evidence may favour treatment allocation
to be dictated by non-medical factors rather than by the
experience of the nephrologist or the needs of the single
patient. We therefore decided to undertake an international
survey among nephrology professionals to ascertain their
view on the best dialysis treatment for different groups of
patients and to see how this correlates with the allocation
of dialysis therapy today.
Subjects and methods
A survey instrument including six questions was designed
and tested for maximum clarity in a pilot survey. The first
three questions asked for opinions about the best initial
dialysis therapy, the best long-term dialysis therapy and
the best extracorporeal dialysis therapy. The fourth ques-
tion asked for the evidence required to rank dialysis ther-
apies. The answers to these four questions are described
and discussed below, while the remaining questions, being
of different nature, will be reported elsewhere. Each ques-
tion had three to four alternative answers and additionally
the option ‘no opinion’. Only one answer was allowed per
question, and when more than one box was marked, the
response was placed in the ‘no opinion’ category. The re-
sponse alternatives reflected the common versions of dial-
ysis therapies, given in broad categories and defined so
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Table 1. Origin and profession of respondents to dialysis opinion survey, 2007
Congress n Physicians (%) Nurses (%) West Europe (%) East Europe (%) Asia (%) Americas (%)
WCN 1029 78 7 8 14 10 62
ERA-EDTA 2041 78 3 23 39 15 4
EuRoPD 772 74 19 45 39 5 3
EDTNA-ERCA 1634 3 82 54 35 1 1
ASN 795 78 3 29 8 16 42
Other 324 35 65 18 – 75 –
Total 6595 57 28 31 28 13 17
as to avoid confusion and exceptions. Peritoneal dialysis
(PD) was described as CAPD/APD (continuous ambula-
tory PD/automated PD). Haemodialysis (HD) was com-
bined with haemodiafiltration (HDF) to comprise all forms
of extracorporeal dialysis.
The questionnaires were distributed during 2007, start-
ing at the World Congress of Nephrology in Rio de Janeiro,
then at the ERA-EDTA Congress in Barcelona, the Eu-
RoPDmeetinginHelsinki,theEDTNA-ERCAConference
in Florence and finally at the ASN Meeting in San Fran-
cisco.Asmallnumberofquestionnaireswerealsocollected
at national meetings in France and Australia. Responses
were anonymous, but information about country of origin,
profession (physician, nurse, administrator or other) and
experience of dialysis was requested. All information was
compiled and summarized by an independent institute.
Results
We received 6595 responses to our survey (Table 1), with
physicians (57%) and Europeans (59%) in majority among
therespondents.Whenaskedabouttheirexperienceofdial-
ysis, 55% of the respondents indicated that they had >10
years’ experience and only 5% gave the answer <1 year.
Best initial dialysis treatment
The first question addressed the initial dialysis treatment
for a typical patient, aged 65 years with one comorbidity.
What was considered to be best for this patient among the
alternatives: CAPD/APD, in-centre HD/HDF or home/self-
care HD/HDF? With self-care therapies among the options,
it was assumed that the selected treatment was the patient’s
choice. The result shows a majority of 49% for PD to be
considered the best dialysis therapy for incident patients
under the given conditions (Figure 1). The support for PD
was in majority in all regions and it was strongest among
Europeanphysicians,60%.Notsurprisingly,thepreference
for PD was exceptionally strong among the participants of
the EuRoPD meeting where 91% of the respondents placed
PD as the best initial dialysis treatment. The other alterna-
tives received the support of 30% for in-centre dialysis and
17% for self-care dialysis from the total group. The order
between the alternatives was the same in all regions and
subgroups with exception for the 539 nurses from East Eu-
rope who placed in-centre dialysis (51%) before PD (30%).
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Fig. 1. Share of nephrology professionals who chose the answer
‘CAPD/APD’ in response to the question ‘What do you consider to be
the best initial dialysis treatment for a patient with planned start, today
and in the near future?’
Best long-term dialysis treatment
The next question asked about the best long-term dialysis
treatment for the majority of patients. The alternatives were
again CAPD/APD, in-centre HD/HDF and home/self-care
HD/HDF. For this question, the issue of frequency was
introduced and the choice of in-centre treatment had to
be given as either 3 times/week or >3 times/week. The
choice of home/self-care HD/HDF was clearly indicated
as >3 times/week, reflecting a common practice for home
HD. Thus, there were four alternatives, two for self-care
dialysis and two for in-centre dialysis. There were also two
alternatives for frequent dialysis, one at home and one in-
centre.
In all regions, frequent application of home/self-care
dialysis was considered the best long-term dialysis treat-
ment, and 34% of the total responses favoured this therapy
(Figure 2). The responses from Asia stand out with 47%
choosing this option. The other three alternatives received
similar support of ∼20% each, with a non-significant dif-
ference between them.
The combined result shows that 56% of the nephrol-
ogy professionals expressed that a self-care administered
therapy (PD or HD/HDF) is better for the patients than
in-centre dialysis. Considering frequency instead, the total
result shows that 52% of physicians and nurses working
with dialysis had the opinion that HD/HDF administered
more frequently than 3 times/week is better for the patients
thanthecurrentregimeof3times/week.Ifweaddthenum-
bers favouring PD, 74% of the respondents clearly said that
frequent or continuous dialysis is better than 3 times/week.What is the best dialysis? 405
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Fig. 2. Share of nephrology professionals who chose the answer
‘home/self-care HD/HDF >3 times/week’ in response to the question
‘What do you consider to be the best long-term dialysis treatment for the
majority of patients, today and in the near future?’
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Fig. 3. Share of nephrology professionals who chose the answers ‘high-
flux HD’ (grey/white) and ‘high-volume HDF’ (black/light grey) in re-
sponse to the question ‘What do you consider to be the best extracorporeal
form of dialysis?’
Best extracorporeal form of dialysis
With ∼90% of dialysis patients worldwide being treated
with an extracorporeal therapy, the next question focused
on the perceived benefits of the major types of this form of
dialysis.Toavoidconfoundingoftheanswerswithbiocom-
patibility issues, all alternatives assumed that membranes
were synthetic, dialysis fluid was ultrapure and infusion
solution, when required, was on-line prepared. The alterna-
tives were low-flux HD, high-flux HD, high-volume HDF
and high-volume haemofiltration (HF).
The total result shows that high-flux HD and high-
volume HDF were preferred to a similar extent by ∼40%
each (Figure 3). HDF was preferred to a greater extent in
Europe, but moving eastwards the preference for high-flux
HD grew and became dominant in Asia, and in the Ameri-
cas there was clear differentiation with high-flux HD being
named the best by 50%. This trend was more pronounced
among physicians than among nurses. The combined sup-
port for high-flux HD and HDF was close to 80% in all
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Fig. 4. Share of nephrology professionals who chose the answer ‘hard
evidence, i.e. improved survival’ in response to the question ‘In order to
consider one form of dialysis superior to another, what is the minimum
level of evidence you would require?’
regions and all subgroups, and this shows an overwhelming
belief that dialysis with high-flux membranes is superior to
dialysis with low-flux membranes. In fact, only 7% of the
total number of respondents indicated low-flux HD as the
best option.
Minimum level of evidence
The final question addressed the view of the respondents
on the minimum level of evidence they would require to
consider one form of therapy superior to another. The al-
ternatives given were to have hard evidence in the form
of improved survival or to have surrogate evidence, which
couldbeimprovementofmarkerssuchasC-reactiveprotein
or left ventricular hypertrophy. It could also be to have so-
called soft evidence, i.e. studies showing better quality of
life. The assumption was made that all study results should
be significant and originate from randomized, controlled
studies. The final option was to have own or colleagues’
experience as the base for ranking.
Among the four alternatives, a clear majority responded
that they would require hard evidence to consider one form
of dialysis superior to another (Figure 4). This was claimed
by 41% of the total, and by over 50% in Asia and America.
Soft evidence was the choice by 25% of the total and surro-
gate evidence by only 16%. The ranking of evidence levels
was the same in the subgroups.
Discussion
Today there is no randomized, controlled study of suffi-
cient dimension showing significantly superior survival of
a cross-section of patients treated with one dialysis therapy
compared to another. Still, this is what a majority of the
nephrology community participating in our survey say that
theyrequiretoconsideronetherapybetterthananother.Yet,
they have an opinion about what is best for their patients,
based on their experience and the evidence available to us
today. It is likely that the type of evidence we would like to
obtain is almost impossible to achieve because of the lack
of financial support, or simply because the design is too406 I. Ledebo and C. Ronco
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Fig. 5. What is the best long-term dialysis treatment? Opinion versus
reality.
difficult and even a randomized controlled trial may not
represent ‘real life’. With this in mind, we should consider
the opinion of professionals as a tool to identify patterns of
practice or ways of thinking and treasure them as important
messages coming from everyday experience.
The majority of the respondents in our survey suggest
PD as an optimal, initial dialysis treatment. There are many
aspects in favour of this view. One of the most often quoted
is the superior preservation of residual renal function in
PD patients when compared to treatment with conventional
haemodialysis [1]. When used for patients on the waiting
list for a transplant, PD has been shown to result in a bet-
ter graft outcome than HD [2]. For many years, registry
data from North America have shown that survival on PD
is better than on HD during the first 2–3 years of dialysis
treatment [3]. Recent data from the USRDS suggest that
survival on PD now shows further improvement for peri-
ods extending beyond the initial years [4]. Starting patients
on PD and transferring them to HD in a timely fashion,
so-called integrated therapy, has been shown to lead to a
survival advantage in comparison to treatment with only
HD [5]. Finally, treatment with PD delays the need for a
functional vascular access, the Achilleus’ heel of all ex-
tracorporeal therapies. The result of our survey confirms
these arguments, but all this is in stark contrast to reality.
Globalinformationonthetreatmentmodeforincidentdial-
ysis patient is not available, but the USRDS shows that 6%
of the new dialysis patients in 2005 were treated with PD.
Thus the use of PD and the views on PD are surprisingly
different.
In-centredialysis,performed3times/week,istodayused
for at least 85% of the prevalent patients worldwide, but
only 23% of the 6595 respondents in our survey consider
this to be the best long-term dialysis treatment (Figure 5).
Instead, self-care dialysis, be it PD or HD, performed at
home or in a self-care setting, is indicated as the best form
of dialysis treatment for the majority of patients by 56%.
In reality, even an optimistic estimation of self-care pa-
tients worldwide would give a figure of maximum 15%. A
number of reasons can be found to explain this large dif-
ference. With a dialysis population of increasing age and
comorbidity, the general condition of the patients may pre-
vent them from assuming responsibility for their dialysis
treatment. Patient motivation is another key factor of vital
importance for the benefits of a self-care therapy to be real-
ized [6]. Then there are all the non-medical factors against
self-caretherapies,includingphysicianbiasandreimburse-
ment disincentives. Ignorance about the practice and value
of self-care therapy among nephrology professionals with
littleornoexperienceofthistreatmentformisoftenquoted
as a cause, but the result of our survey does not support that
notion. Other surveys have also shown a positive attitude
towards self-care therapies among nephrologists. In 2003,
Mendelssohn published the results from a series of sur-
veys among nephrologists in Canada, the UK and the USA
[7]. When asked to indicate the preferred distribution of
treatment modes for optimal quality of life and wellness,
the physicians in the different countries recommended self-
care therapy for 45–49% of the patients.
During the past 10 years, the interest in self-care HD
has increased in parallel with a growing number of positive
reports on significant clinical benefits from treatment with
frequent dialysis, performed as short sessions during day-
timeorlongnocturnaldialysis,5–7times/week[8].Already
today the trips to and from the dialysis unit 3 times/week
are a time-consuming burden to patients and with more
frequent dialysis the practical disadvantages may offset the
therapeutic benefits, unless dialysis can be organized to
take place at home. Thus, the realization of more frequent
dialysis is closely associated with self-care HD. The posi-
tive attitude among nephrology professionals to this form
of dialysis therapy is an encouraging signal to healthcare
providers and industry to develop programmes and prod-
ucts that enable more patients to benefit from self-care
treatment.
Two recent major studies have addressed the issue of
high-flux dialysis versus low-flux dialysis in a prospective,
randomized, controlled design. The HEMO study found
no difference in the primary outcome parameter, all cause
mortality, or any of the main secondary outcomes between
the groups of 921 patients treated with high-flux mem-
branes and the 925 patients using low-flux membranes [9].
However, they did find that high-flux dialysis resulted in
20% reduced risk of cardiac death, a secondary combined
outcome parameter, and 32% reduced mortality risk in the
subgroup of patients treated with dialysis for >3.7 years
before the start of the study. The MPO study was designed
to compensate for some of the shortcomings of the HEMO
study by only including incident patients and only allowing
single use of filters [10]. Looking only at patients whose
albumin levels were ≤4.0 g/dl at the time of enrolment
in the study, they found a survival benefit of 37% for the
250 patients treated with high-flux membranes compared
to the 243 patients treated with low-flux membranes. No
difference in outcome was seen when all 647 study patients
wereconsidered.However,amongthe150diabeticpatients,
there was also a significant survival benefit from treatment
with high-flux membranes. The result of the MPO study
has been widely reported, but its publication as a full paper
is still pending.What is the best dialysis? 407
High-fluxdialysisisHDperformedwithhigh-fluxmem-
branes. Compared to low-flux dialysis, the increased mem-
brane permeability results in removal of an extended range
ofsolutesand increased volumes ofultrafiltration.Because
the excess ultrafiltration is compensated by backfiltration
of dialysis fluid, high-flux dialysis comprises a certain
amount of convective clearance with additional removal
of large solutes. When compared with HDF, we could say
that high-flux HD is HDF with a limited amount of convec-
tionandwithouttheuseofanexternalsubstitutionsolution.
Therefore, it is logical to assume that benefits of high-flux
dialysis might be extended when moving to HDF, which in
the high-volume version provides an additional convective
transport,andthusincreasedremovaloflargersolutes.This
is also supported by observational data from DOPPS where
HDF patients treated with exchange volumes exceeding 15
l per session showed significantly better survival than HDF
patients having a lower volume of convective removal and
patients on high-flux dialysis [11]. Other benefits associ-
ated with high-flux dialysis, such as improved blood pres-
sure control, anaemia management and nutritional status
and reduced levels of ß2-microglobulin, are all to a greater
extent also reported with HDF [12].
Regarding the extracorporeal treatments, there are again
large differences between the opinion expressed in our sur-
vey and therapies used today. We estimate that one-third
of prevalent patients on HD are still treated with low-flux
membranes, at least half of them cellulosic, but only 7%
rated low-flux dialysis with synthetic membranes as best
for the patients. The remaining two-thirds are treated with
high-flux membranes, the majority in HD mode.
High-volume HDF requires the use of an on-line pre-
pared substitution solution and is therefore only practiced
in countries where this form of sterilization is approved
by the authorities or recognized by the community [13].
Most European countries have a growing population of pa-
tients treated with on-line HDF and its use is spreading
in Australia and parts of Asia [14]. On-line HDF is also
starting to be practiced in Canada, but is still not approved
in the USA. There are probably close to 50 000 patients
on HDF only in Europe, the majority in Western Europe
where this therapy is already long-established. The survey
result therefore reflects the practical experience of HDF,
with the strongest conviction about its benefits in Europe,
and this falling as we move eastwards, being replaced by a
preference for high-flux HD. Still, the belief in the value of
high-flux membranes is equally strong everywhere.
The opinions expressed by the nephrology professionals
inoursurveycloselyreflectedtheongoingscientificdiscus-
sionaroundclinicalbenefitsreportedfornewtherapiesand
new forms of old therapies. Still, the responders expressed
their belief in evidence-based medicine by indicating that a
definite ranking of therapies would require evidence of su-
periorsurvival.However,itisunlikelythatwewilleverhave
such evidence for PD versus HD, for in-centre HD versus
home HD, for HD 3 times/week versus HD 5–6 times/week
or for high-flux HD versus high-volume HDF, consider-
ing past and ongoing study efforts. The number of patients
and the resources required to conduct adequately powered,
prospective, randomized, controlled studies of these issues
is probably out of reach for the nephrology community. In-
stead, we will have to look with critical eyes and statistical
rigour at the data available to us [15].
We have not referred to economy once throughout this
discussion,althougheconomicalissuesarecertainlyamong
the reasons for reality to be so different from the opinion
of the medical professionals about what is best for their
patients. However, while economical limitations may ex-
plain why synthetic high-flux membranes are not used for
all patients, they do not serve this purpose to justify why
self-care dialysis, PD as well as HD, is not used for more
patients. Furthermore, economy does not explain why the
authorities in some countries do not accept controlled, step-
wise ultrafiltration for the preparation of infusion solutions
for convective therapies, which would allow a more cost-
effective and, by many considered superior form of dialysis
therapy, high-volume HDF, to be more widely practiced.
So non-medical issues, besides economy, appear to play a
major role in treatment allocation.
The respondents in this survey were not randomly se-
lected and may therefore not represent an international
cross-section of nephrology professionals. They do, how-
ever, make up a very large sample of physicians and nurses
who attended international congresses in nephrology and
dialysis during 2007, and their responses to our questions
are based on long experience of dialysis, over 10 years on
average. Their opinions closely reflect what is considered
best practice in the nephrology community today and this
would likely be a guide to how they would treat the major-
ity of their patients provided non-medical factors did not
prevent them.
In conclusion, our survey among 6595 international
nephrology professionals showed that the majority consid-
ersPDtobethebestinitialdialysistherapy,whilefrequently
applied, self-care dialysis, when possible in a home envi-
ronment, is selected as the best long-term therapy. The best
extracorporeal treatment form is dialysis with a high-flux
membrane, applied either in HD or in HDF. These opinions
appear to reflect the present view on best clinical practice,
but they are far from the clinical reality, where non-medical
factors seem to have a strong influence.
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